Investments
15Portfolio Exits
4About Vital Venture Capital
Vital Venture Capital is a venture capital firm based in Bethesda, Maryland, focusing on patentable science technologies and business software. The firm has invested in 17 portfolio companies since its formation in 2008. Partners contribute expertise in marketing, sales, implementation, product development, intellectual property, and finance to the management teams of their investment companies.
Vital Venture Capital Headquarter Location
7101 Wisconsin Avenue Suite 1210
Bethesda, Maryland, 20814,
United States
415-297-6451
Expert Collections containing Vital Venture Capital
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Vital Venture Capital in 1 Expert Collection, including Synthetic Biology.
Synthetic Biology
382 items
Latest Vital Venture Capital News
Apr 12, 2018
RubrYc Therapeutics Completes $10M Million Series A Financing SAN RAMON, Calif., April 11, 2018-- RubrYc Therapeutics, Inc., a biotherapeutics discovery business, announced today it has closed a $10 million Series A Preferred Equity financing round led by Third Point Ventures, with participation by Paladin Capital Group and Vital Venture Capital. "Our development of unique chemical libraries has allowed us to map the surfaces of drug targets with unprecedented resolution, and to identify off target binding events that hamper drug discovery and development," said Dr. Isaac Bright, CEO of RubrYc Therapeutics. "With our Series A financing, which completes our spin-off from HealthTell, Inc., we are continuing to build our antibody discovery platform, proprietary pipeline of therapeutic candidates, and actively initiating new pharmaceutical partnerships." RubrYc is focused on improving drug discovery through proprietary insights into critical interactions at the drug/target interface. Using diverse chemical libraries developed and supplied by HealthTell, Inc., RubrYc is training algorithms that inform improved decision-making throughout drug discovery. The company will be collaborating with biotechnology companies in early drug discovery and developing its own molecules. "I am excited to launch RubrYc Therapeutics and believe that the company's applications of our technology address important challenges in antibody characterization. We are already seeing results in the earliest phases of RubrYc programs, and I look forward to supporting the team as the company grows," said Bill Colston, CEO of HealthTell and Executive Chairman of RubrYc Therapeutics. About RubrYc Therapeutics Founded in 2017, RubrYc Therapeutics, Inc. emerged as a biotherapeutic discovery partner of immunomics leader HealthTell, Inc. The Company has exclusive rights to HealthTell technology and combines binding information from diverse chemical library assays, with gold-standard drug discovery methods to develop biotherapeutic candidates that are optimized for clinical development. Contact:
Vital Venture Capital Investments
15 Investments
Vital Venture Capital has made 15 investments. Their latest investment was in Ginkgo Bioworks as part of their Series E on September 9, 2019.
Vital Venture Capital Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
9/19/2019 | Series E | Ginkgo Bioworks | $290M | No | 32 | |
4/11/2018 | Series A | RubrYc Therapeutics | $10M | Yes | 5 | |
12/14/2017 | Series D | Ginkgo Bioworks | $275M | Yes | 15 | |
3/9/2016 | Series B | |||||
1/19/2016 | Series D |
Date | 9/19/2019 | 4/11/2018 | 12/14/2017 | 3/9/2016 | 1/19/2016 |
---|---|---|---|---|---|
Round | Series E | Series A | Series D | Series B | Series D |
Company | Ginkgo Bioworks | RubrYc Therapeutics | Ginkgo Bioworks | ||
Amount | $290M | $10M | $275M | ||
New? | No | Yes | Yes | ||
Co-Investors | |||||
Sources | 32 | 5 | 15 |
Vital Venture Capital Portfolio Exits
4 Portfolio Exits
Vital Venture Capital has 4 portfolio exits. Their latest portfolio exit was Ginkgo Bioworks on September 17, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
9/17/2021 | Reverse Merger | 10 | |||
Date | 9/17/2021 | |||
---|---|---|---|---|
Exit | Reverse Merger | |||
Companies | ||||
Valuation | ||||
Acquirer | ||||
Sources | 10 |
Vital Venture Capital Team
1 Team Member
Vital Venture Capital has 1 team member, including current Founding Partner, David Phelps.
Name | Work History | Title | Status |
---|---|---|---|
David Phelps | Founding Partner | Current |
Name | David Phelps |
---|---|
Work History | |
Title | Founding Partner |
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.